BioSpace News Archive

Dec. 19, 2018 13:00 UTC BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time. Both the presentation and question and answer session that follows at 3:00 p.m. will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegeneti

Reprieve Cardiovascular™, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced new clinical study results demonstrating improvements in the ability of Reprieve-Guided Diuretic Therapy to optimize fluid management for people with Acute Decompensated Heart Failure (ADHF).

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization), an international, Phase 3 clinical trial of AR101 in peanut-allergic children ages 1–3 years. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.

Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.

ZappRx announced today that it has entered into an agreement with Genentech. The agreement will start by seeking to improve patient access to specialty drugs in IPF, with an option to continue in allergic asthma, and chronic idiopathic urticaria.

Establishes a new focused global consumer healthcare business with the independence and sustainability to deliver significant value

Satralizumab monotherapy significantly reduced risk of relapse

Strategic review process announced in June concludes with a project to sell UPSA consumer health business

Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors.